## Sawai Group Holdings

## <u>Sawai Group Holdings Announces Posting of Impairment Loss and Revision of Forecast at</u> <u>Sawai Pharmaceutical</u>

Name	Sawai Group Holdings Co., Ltd. (Securities Code: 4887)
Fiscal year	April 1 to March 31
Current fiscal year	Fiscal 2021 (April 1, 2021 to March 31, 2022)
Overview	Sawai Group Holdings announces that its wholly owned subsidiary, Sawai Pharmaceutical Co., Ltd., is forecast to post impairment loss on intangible assets for fiscal 2020 and has revised its forecast of results for fiscal 2020.

## Posting Impairment Loss on Intangible Assets

Details	Source Department desided that concerning the license veloted to
Details	Sawai Pharmaceutical decided that, concerning the license related to
	the manufacturing and sale of Tosymra <sup>™</sup> held by the U.S. segment,
	the book value will surpass collectable amount with the decreased
	profitability due to the lower rate of patients utilizing medicine, fewer
	in-person physician office visits, the release of competing products, etc.
	in the U.S. Accordingly, it is forecast that Sawai Pharmaceutical will
	post impairment loss on intangible assets of 5,572 million yen for fiscal
	2020.

## **Revised Forecast for Fiscal 2020**

	Sales [mn yen]	Core operating profit [mn yen]	Operating profit [mn yen]	Profit before tax [mn yen]	Profit attributable to owners of parent [yen]	Basic earnings per share [yen]		
Previous forecast (May 14, 2020) (A)	200,200	34,800	26,850	26,550	20,050	457.85		
Revised forecast (B)	187,200	34,000	18,850	18,450	12,300	280.89		
Net change (B)-(A)	-13,000	-800	-8,000	-8,100	-7,750			
Change (%)	-6.5	-2.3	-29.8	-30.5	-38.7			

Inquiries	Group Public Relations and Investor Relations Office, Sawai Group Holdings Co., Ltd.
	E-mail: ir@sawai.co.jp URL: https://global.sawaigroup.holdings

**Disclaimer:** Corporate Flash is a service provided by Transpacific Enterprises as part of Japan Market Flash services. Any inquiries concerning the content of the posted information should be made directly to the contact at the concerned company. The information provided herein does not constitute business, legal, investment or tax advice, and is presented without any representation or warranty whatsoever as to the accuracy or completeness of the information, or whether it reflects the most current developments. Parties seeking advice should consult with business, legal, investment or tax counsel familiar with their particular circumstances. The sole purpose of this service is to provide information for the users of the service, and is not to solicit investment, or to recommend an investment in a specific issue, etc.